Skip to main content
Year archive

Hansa Biopharma — 2018 filings

All 71 regulatory filings released by Hansa Biopharma (HNSA) in 2018, sourced directly from the official regulator.

71 Filings
2018 Period
2018 filings (71)
Filing Released Lang
Hansa Medical AB under namnbyte till Hansa Biopharma AB
Regulatory Filings
2018-12-20 Swedish
Hansa Medical AB to change name to Hansa Biopharma AB
Regulatory Filings
2018-12-20 English
Kommuniké från extra bolagsstämma i Hansa Medical AB (publ)
AGM Information
2018-12-11 Swedish
Bulletin from the Extraordinary General Meeting of Hansa Medical AB (publ)
AGM Information
2018-12-11 English
Hansa Medical AB Announces Increase in Number of Shares and Votes
Share Issue/Capital Change
2018-11-30 English
Ökning av antalet aktier och röster i Hansa Medical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2018-11-30 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification
2018-11-19 English
Hansa Medical har genomfört en riktad nyemission om 453 MSEK / 50 MUSD
Capital/Financing Update
2018-11-14 Swedish
Hansa Medical Announces Closing of SEK 453 / $50 Million Directed Share Issue
Share Issue/Capital Change
2018-11-14 English
EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE I ELLER TILL USA, STORBRITANNIEN, KANADA, AUSTRALIEN ELLER JAPAN.
Share Issue/Capital Change
2018-11-13 Swedish
NOT FOR DISTRIBUTION IN THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA OR JAPAN.
Share Issue/Capital Change
2018-11-13 English
Kallelse till extra bolagsstämma i Hansa Medical AB (publ)
AGM Information
2018-11-09 Swedish
Notice of Extraordinary General Meeting of Hansa Medical AB (publ)
AGM Information
2018-11-09 English
Interim / Quarterly Report 2018
Interim / Quarterly Report 9M 2018
2018-11-01 English
Interim / Quarterly Report 2018
Interim / Quarterly Report 9M 2018
2018-11-01 Swedish
Ökning av antalet aktier och röster i Hansa Medical AB (publ)
Share Issue/Capital Change
2018-10-31 Swedish
Increase of Number of Shares and Votes in Hansa Medical AB (publ)
Share Issue/Capital Change
2018-10-31 English
Kommuniké från extra bolagsstämma i Hansa Medical AB (publ)
AGM Information
2018-10-29 Swedish
Bulletin from the Extraordinary General Meeting of Hansa Medical AB
Share Issue/Capital Change
2018-10-29 English
Presentation at ASN Kidney Week 2018 Highlights Stable Renal Function at up to 24 Months Following Transplantation Enabled by Imlifidase
Regulatory Filings
2018-10-26 English
Resultat presenterade vid ASN Kidney Week 2018 belyser fortsatt stabil njurfunktion i upp till 24 månader efter transplantation
Regulatory Filings
2018-10-26 Swedish
Hansa Medical erhåller positivt utlåtande gällande särläkemedelsstatus i EU för imlifidase och behandling av anti-GBM sjukdom
Regulatory Filings
2018-10-24 Swedish
Hansa Medical Receives Positive Opinion for Orphan Drug Designation in the EU for Imlifidase for Anti-GBM Disease
Regulatory Filings
2018-10-24 English
Hansa Medical erhåller Fast Track-status för imlifidase inom transplantation av FDA
Regulatory Filings
2018-10-17 Swedish
Hansa Medical Receives FDA Fast Track Designation for Imlifidase for Transplantation
Regulatory Filings
2018-10-17 English
Notice of Extraordinary General Meeting of Hansa Medical AB (publ)
AGM Information
2018-10-05 English
Kallelse till extra bolagsstämma i Hansa Medical AB (publ)
AGM Information
2018-10-05 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification
2018-10-05 English
Hansa Medical rapporterar positiva finala övergripande resultat från två fas 2-studier med imlifidas vid njurtransplantation
Regulatory Filings
2018-09-27 Swedish
Hansa Medical Reports Positive Final Top Line Results from Two Phase 2 Studies of Imlifidase for Kidney Transplantation
Regulatory Filings
2018-09-27 English
Hansa Medical utser Vincenza Nigro till Vice President, Global Medical Affairs
Board/Management Information
2018-09-17 Swedish
Hansa Medical Announces Appointment of Vincenza Nigro as Vice President, Global Medical Affairs
Board/Management Information
2018-09-17 English
Emission och återköp av C-aktier för incitamentsprogram
Share Issue/Capital Change
2018-09-06 Swedish
Issue and repurchase of class C shares for incentive program
Transaction in Own Shares
2018-09-06 English
Increase of number of shares and votes in Hansa Medical AB (publ)
Share Issue/Capital Change
2018-07-31 English
Ökning av antalet aktier och röster i HansaMedical AB (publ)
Share Issue/Capital Change
2018-07-31 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report H1 2018
2018-07-19 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q2 2018
2018-07-19 English
Hansa Medical bjuder in till webbsänd telefonpresentation av bolagets delårsrapport för andra kvartalet 2018
Report Publication Announcement
2018-07-12 Swedish
Hansa Medical to Host Conference Call to Provide Second Quarter 2018 Business Update
Report Publication Announcement
2018-07-12 English
Hansa Medicals läkemedelskandidat imlifidase (IdeS) beviljas särläkemedelsstatus (Orphan Drug Designation) av FDA för behandling av anti-GBM sjukdom
Regulatory Filings
2018-07-09 Swedish
Hansa Medical lead candidate imlifidase (IdeS) granted orphan drug designation by the FDA for anti-GBM antibody disease
Regulatory Filings
2018-07-09 English
Increase of number of shares in Hansa Medical AB (publ)
Share Issue/Capital Change
2018-06-29 English
Ökning av antalet aktier i Hansa Medical AB (publ)
Share Issue/Capital Change
2018-06-29 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification
2018-06-11 English
Presentation vid 2018 American Transplant Congress visar den långsiktiga risk/nytta-profilen för imlifidase (IdeS) vid njurtransplantation
Regulatory Filings
2018-06-06 Swedish
Presentation at the 2018 American Transplant Congress highlights the long-term risk-benefit profile of imlifidase (IdeS) in kidney transplantation
Regulatory Filings
2018-06-06 English
Long-term follow up data from investigator-initiated Phase II study with imlifidase (IdeS) to be presented at 2018 American Transplant Congress (ATC)
Regulatory Filings
2018-05-30 English
Uppföljningsresultat från prövarinitierad fas II-studie med imlifidase (IdeS) kommer att presenteras vid 2018 American Transplant Congress (ATC)
Regulatory Filings
2018-05-30 Swedish
Kommuniké från årsstämma i Hansa Medical AB (publ)
AGM Information
2018-05-29 Swedish
Bulletin from the Annual General Meeting in Hansa Medical AB (publ)
AGM Information
2018-05-29 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Q1 2018
2018-04-25 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q1 2018
2018-04-25 English
Notice to Annual General Meeting in Hansa Medical AB (publ)
AGM Information
2018-04-25 English
Kallelse till årsstämma i Hansa Medical AB (publ)
AGM Information
2018-04-25 Swedish
Annual Report 2017
Annual Report FY 2017
2018-04-11 Swedish
Annual Report 2017
Annual Report FY 2017
2018-04-11 English
Resultaten från Hansa Medicals första fas II-studie med IdeS publiceras av American Journal of Transplantation
Regulatory Filings
2018-03-21 Swedish
The American Journal of Transplantation publishes results from Hansa Medical's first Phase II study with IdeS
Regulatory Filings
2018-03-21 English
Søren Tulstrup utsedd till ny VD och koncernchef för Hansa Medical
Board/Management Information
2018-03-20 Swedish
Søren Tulstrup appointed new President and CEO of Hansa Medical
Board/Management Information
2018-03-20 English
Hansa Medical beviljas särläkemedelsstatus för IdeS och behandling av Guillain-Barrés syndrom i USA
Regulatory Filings
2018-02-16 Swedish
Hansa Medical receives FDA Orphan Drug Designation for IdeS and the treatment of Guillain-Barré syndrome
Regulatory Filings
2018-02-16 English
Interim / Quarterly Report 2017
Interim / Quarterly Report FY 2017
2018-02-14 English
Interim / Quarterly Report 2017
Interim / Quarterly Report FY 2017
2018-02-14 Swedish
Increase of number of votes in Hansa Medical AB (publ)
Share Issue/Capital Change
2018-01-31 English
Ökning av antalet röster i Hansa Medical AB (publ)
Share Issue/Capital Change
2018-01-31 Swedish
Fullbordad patientrekrytering till Hansa Medicals internationella multicenterstudie Highdes
Legal Proceedings Report
2018-01-04 Swedish
Completed enrollment in Hansa Medical’s international multi-center Phase II study Highdes
Regulatory Filings
2018-01-04 English
Slutförd rekrytering av patienter till amerikansk fas II-studie med IdeS i högsensitiserade patienter
Regulatory Filings
2018-01-03 Swedish
Finalized enrollment in US Phase II study with IdeS in highly sensitized patients
Regulatory Filings
2018-01-03 English